Evropská unie - angličtina - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - corbilta is indicated for the treatment of adult patients with parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; powdered cellulose; sodium sulfate; trehalose dihydrate; magnesium stearate; carmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; microcrystalline cellulose; trehalose dihydrate; carmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - levodopa, quantity: 150 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; powdered cellulose; sodium sulfate; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; hyprolose; magnesium stearate; powdered cellulose; carmellose sodium; sodium sulfate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; powdered cellulose; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Spojené státy - angličtina - NLM (National Library of Medicine)

wockhardt usa llc. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat patients with idiopathic parkinson’s disease who experience the signs and symptoms of end-of-dose "wearing-off" (see clinical pharmacology, clinical studies). entacapone tablets’ effectiveness has not been systematically evaluated in patients with idiopathic parkinson’s disease who do not experience end-of-dose "wearing-off". entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical trials have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Spojené státy - angličtina - NLM (National Library of Medicine)

sunshine lake pharma co., ltd. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone tablets usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with parkinson's disease (see clinical pharmacology, clinical studies). entacapone's effectiveness has not been systematically evaluated in patients with parkinson's disease who do not experience end-of-dose "wearing-off". entacapone is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Spojené státy - angličtina - NLM (National Library of Medicine)

lannett company, inc. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone tablets usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with parkinson's disease (see clinical pharmacology, clinical studies). entacapone's effectiveness has not been systematically evaluated in patients with parkinson's disease who do not experience end-of-dose "wearing-off". entacapone is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Spojené státy - angličtina - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies). entacapone tablet’s effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.